Biological pharmaceuticals including vaccines, antibodies, and hormones are increasingly produced using animal-derived cell lines in bioreactors, raising questions about the welfare of source animals for cell line establishment.
Pharmaceutical bioreactor production represents an area where animal welfare improvements align with product quality improvements, creating unusual market incentives for change. Animal-free culture media generally provide better batch consistency than serum-containing alternatives, meaning welfare-driven transitions often improve product quality simultaneously. The primary welfare concern — fetal bovine serum collection — can be largely eliminated through industry transition to chemically defined media, and this transition is underway in leading facilities. Regulatory requirements and procurement criteria that incentivise animal-free media adoption would accelerate an already positive trend.